SIV vaccine

Drug Profile

SIV vaccine

Alternative Names: SIVdelta3

Latest Information Update: 16 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocon; Institut Pasteur
  • Developer Chiron Corporation; Endocon; Harvard Medical School; National Institutes of Health (USA); New England Regional Primate Center; Nonindustrial source; TSI Mason Laboratories; University of California, Davis
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 16 Oct 2005 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 02 Jun 1999 A study has been added to the Viral Infections pharmacodynamics section
  • 22 Apr 1997 An in vitro study has been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top